Could Incoming Threats Sink MannKind Corporation?
Big Pharma suspected that MannKind's Afrezza would make its way to the market eventually. Now that its here, what does the industry have in its pipeline that could potentially slow adoption?
MannKind, Front and Center: The Best Product Doesn’t Always Equal the Best Stock
The Motley Fool's own Michael Douglass and Todd Campbell dig into MannKind Corp.'s first quarter earnings to see if MannKind is a bargain, or a bust.